Limits...
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegfellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl-Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R - J. Allergy Clin. Immunol. (2014)

Bottom Line: BM321, BM322, BM325, and BM326 showed almost completely abolished allergenic activity and induced significantly reduced T-cell proliferation and release of proinflammatory cytokines in patients' PBMCs compared with grass pollen allergens.On immunization, they induced allergen-specific IgG antibodies, which inhibited patients' IgE binding to all 4 major allergens of grass pollen, as well as allergen-induced basophil activation.A recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergy.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Show MeSH

Related in: MedlinePlus

A, Scheme of treatment with BM32 in a murine model of grass pollen allergy. Mice were sensitized by means of subcutaneous (s.c.) injection and by means of intranasal challenge with recombinant grass pollen allergens split into 2 groups, one of which was treated with BM32 and the other with PBS alone. Allergen-induced basophil activation testing was done on day 188. B, Basophils from grass pollen–sensitized mice treated with BM32 (n = 6) or PBS (n = 6, x-axis) were stimulated with either Phl p 1, Phl p 5, or Phl p 6 (top line). Shown are the mean fluorescence intensities (MFIs; y-axis) of CD200R expression for the mice in each group. Medians are indicated as horizontal bars for each group, and significant differences between the BM32 and PBS groups are indicated. *P < .05. The horizontal line indicates mean baseline expression of CD200R expression for the medium controls.
© Copyright Policy - CC BY
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4418753&req=5

fig7: A, Scheme of treatment with BM32 in a murine model of grass pollen allergy. Mice were sensitized by means of subcutaneous (s.c.) injection and by means of intranasal challenge with recombinant grass pollen allergens split into 2 groups, one of which was treated with BM32 and the other with PBS alone. Allergen-induced basophil activation testing was done on day 188. B, Basophils from grass pollen–sensitized mice treated with BM32 (n = 6) or PBS (n = 6, x-axis) were stimulated with either Phl p 1, Phl p 5, or Phl p 6 (top line). Shown are the mean fluorescence intensities (MFIs; y-axis) of CD200R expression for the mice in each group. Medians are indicated as horizontal bars for each group, and significant differences between the BM32 and PBS groups are indicated. *P < .05. The horizontal line indicates mean baseline expression of CD200R expression for the medium controls.

Mentions: Similar results were obtained in an in vivo model of grass pollen allergy (Fig 7, A). Treatment with BM32 reduced allergen-induced basophil activation in sensitized mice significantly for Phl p 1 and Phl p 6 (P < .05) when compared with that seen in PBS-treated mice. A reduction of basophil activation was noted also for Phl p 5 stimulation (Fig 7, B).


Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegfellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl-Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R - J. Allergy Clin. Immunol. (2014)

A, Scheme of treatment with BM32 in a murine model of grass pollen allergy. Mice were sensitized by means of subcutaneous (s.c.) injection and by means of intranasal challenge with recombinant grass pollen allergens split into 2 groups, one of which was treated with BM32 and the other with PBS alone. Allergen-induced basophil activation testing was done on day 188. B, Basophils from grass pollen–sensitized mice treated with BM32 (n = 6) or PBS (n = 6, x-axis) were stimulated with either Phl p 1, Phl p 5, or Phl p 6 (top line). Shown are the mean fluorescence intensities (MFIs; y-axis) of CD200R expression for the mice in each group. Medians are indicated as horizontal bars for each group, and significant differences between the BM32 and PBS groups are indicated. *P < .05. The horizontal line indicates mean baseline expression of CD200R expression for the medium controls.
© Copyright Policy - CC BY
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4418753&req=5

fig7: A, Scheme of treatment with BM32 in a murine model of grass pollen allergy. Mice were sensitized by means of subcutaneous (s.c.) injection and by means of intranasal challenge with recombinant grass pollen allergens split into 2 groups, one of which was treated with BM32 and the other with PBS alone. Allergen-induced basophil activation testing was done on day 188. B, Basophils from grass pollen–sensitized mice treated with BM32 (n = 6) or PBS (n = 6, x-axis) were stimulated with either Phl p 1, Phl p 5, or Phl p 6 (top line). Shown are the mean fluorescence intensities (MFIs; y-axis) of CD200R expression for the mice in each group. Medians are indicated as horizontal bars for each group, and significant differences between the BM32 and PBS groups are indicated. *P < .05. The horizontal line indicates mean baseline expression of CD200R expression for the medium controls.
Mentions: Similar results were obtained in an in vivo model of grass pollen allergy (Fig 7, A). Treatment with BM32 reduced allergen-induced basophil activation in sensitized mice significantly for Phl p 1 and Phl p 6 (P < .05) when compared with that seen in PBS-treated mice. A reduction of basophil activation was noted also for Phl p 5 stimulation (Fig 7, B).

Bottom Line: BM321, BM322, BM325, and BM326 showed almost completely abolished allergenic activity and induced significantly reduced T-cell proliferation and release of proinflammatory cytokines in patients' PBMCs compared with grass pollen allergens.On immunization, they induced allergen-specific IgG antibodies, which inhibited patients' IgE binding to all 4 major allergens of grass pollen, as well as allergen-induced basophil activation.A recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergy.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Show MeSH
Related in: MedlinePlus